Status:
WITHDRAWN
Post Marketing Surveillance To Observe Safety And Efficacy Of Enbrel In Pediatric Patients With Psoriasis
Lead Sponsor:
Pfizer
Conditions:
Pediatric Psoriasis
Eligibility:
All Genders
8-17 years
Brief Summary
Enbrel was first approved as new medicine on 06 Oct 2003 in Korea and the indication of Pediatric Psoriasis was approved on 23 Sep 2009. However, as required for any new indication approved by Korea F...
Detailed Description
All patients enrolled should meet the usual prescribing criteria for Enbrel in psoriasis as per the local product information for usage.
Eligibility Criteria
Inclusion
- Children and adolescents aged 8 years to 17 years at time of consent
- Chronic severe psoriasis patients who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies
Exclusion
- Patients with known hypersensitivity to Enbrel or any component of the product
- Patients with active infections including chronic or localized infections such as tuberculosis (Treatment of Enbrel should not be initiated)
Key Trial Info
Start Date :
March 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2013
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01432249
Start Date
March 1 2013
End Date
September 1 2013
Last Update
November 18 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.